Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction
Kevin G. Volpp(Philadelphia VA Medical Center), David A. Asch(University of Pennsylvania), Aaron Smith–McLallen(Highmark Blue Cross Blue Shield), Laurie Norton(University of Pennsylvania), Shivan J. Mehta(Philadelphia VA Medical Center), R. K. S. Lim(University of Pennsylvania Health System), Noora Marcus, Nathan Negin(Horizon Blue Cross Blue Shield of New Jersey), Brian Drachman(Penn Presbyterian Medical Center), Kristen Caldarella(University of Pennsylvania), Daniel M. Kolansky(Hospital of the University of Pennsylvania), Mike Relish(Humana (United States)), Tova Levin(Humana (United States)), Christian Terwiesch(University of Pennsylvania), Wenli Wang(University of Pennsylvania Health System), Richard Snyder(Highmark Blue Cross Blue Shield), Andrea B. Troxel(Andover Eye Associates), Jingsan Zhu(University of Pennsylvania), Claire M. Spettell
Cited by 135
Related Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
|New England Journal of Medicine|2020|1.1k
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis
|Circulation Heart Failure|2019|560
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis
|Journal of the American College of Cardiology|2016|540